Balasubramanian, Adithya
Metcalfe, Michael J.
Wagenheim, Gavin
Xiao, Lianchun
Papadopoulos, John
Navai, Neema
Davis, John W.
Karam, Jose A.
Kamat, Ashish M.
Wood, Christopher G.
Dinney, Colin P.
Matin, Surena F.
Article History
Received: 27 February 2018
Accepted: 21 May 2018
First Online: 26 May 2018
Compliance with ethical standards
:
: A. Kamat is a consultant to the following companies; Photocure, Telesta Therapeutics, Sanofi, Merck, Abbott Molecular, Theralase, Heat Biologics, Spectrum Pharmaceuticals and Oncogenix and has received research funding from FKD Industries; In addition, A. Kamat has a patent CyPRIT-Cytokine Panel for Response to Intravesical Immunotherapy pending. J. Karam is a consultant to the following companies: Pfizer, EMD Serono and Novartis. C. Dinney is a paid consultant to FKD Therapies. The corresponding author is a consultant to the following companies: Taris, Urogen, and Peloton Therapeutics and has received research funding from AT&T Foundation and Specialized Program in Oncology Research (SPORE).
: This review does not involve human subjects and meets Helsinki declaration for protection of human subjects.